SGMT

Over the past six months, Sagimet Biosciences' stock has seen fluctuations, trading at $9.03 on October 6, 2026, reflecting a 19.93% decrease in the past month, but a 19.84% increase over the last 12 months and a 47.97% year-to-date return. The share price on September 18, 2026, was $11.09, a 62.85% increase from September 22, 2025. In October 2026, Sagimet announced positive 52-week results from its license partner Ascletis' Phase 3 open-label extension clinical trial of denifanstat in acne and closed an underwritten offering, raising approximately $115.0 million. In September 2026, the company hosted a virtual KOL event to update on denifanstat's 52-week data and the planned AURORA Phase 3 clinical trial in the U.S., also announcing the pricing of its $115.0 million underwritten offering. August 2026 saw Sagimet report operational progress for its AURORA U.S. Phase 3 trial of denifanstat in moderate to severe acne, with patient screening expected in October 2026 and first enrollment planned for Q4 2026. In April 2026, the company secured $163.9 million in net proceeds through another underwritten stock offering. Wall Street analysts have shown a bullish sentiment with a 'Strong Buy' consensus from all 6 analysts and an average price target of $32.33, with several analysts raising their price targets.